Life Sciences IPOs Take a Breather December 02, 2013 | Press Release
Booming IPO Market Improving M&A Terms for Private Biotechs November 01, 2013 | Press Release
ADMA Biologics, Inc. Announces Pricing October 18, 2013 | Press ReleaseSee all News
FDA Commissioner Dr. Margaret Hamburg headlines at the Burrill Annual Personalized Medicine MeetingSeptember 16, 2009
SAN FRANCISCO - Newly confirmed FDA Commissioner Dr. Margaret Hamburg has vowed to enhance the FDA’s focus toward improving public health and at The Burrill Personalized Medicine Meeting, November 9-10 in San Francisco. Hamburg will provide attendees with the latest perspectives on regulatory policies and government initiatives that will help shape the adoption and impact of personalized medicine on healthcare.
However, in order for personalized medicine to be fully adopted into clinical practice it will require changes in regulation, and legislative protections for privacy. Governments will need to play a bigger role in funding and coordinating research while also eliminating regulatory hurdles that currently hinder the creation and adoption of innovative products and medical treatments.
Also on the first day Dr. George Poste, Chief Scientist, Complex Adaptive Systems Initiative at Arizona State University will present a second keynote entitled: “Health Technology Acceleration and Convergence,” where he will discuss the emergence of a new healthcare ecosystem based on increasingly comprehensive profiling of disease risk and health status.
“We are starting to see personalization of therapy become not just more widespread, but a best practice and a standard of care in certain disease areas. The pace of that trend will only increase as more and more targeted treatments reach the marketplace,” said G. Steven Burrill, CEO, Burrill & Company and organizer of the meeting.
Further details on the agenda may be obtained from: http://www.burrillandco.com/personalized_medicine_2009/